194 results
8-K
EX-99.1
INCY
Incyte Corp.
30 Apr 24
Incyte Reports 2024 First Quarter Financial Results and Provides Updates
7:10am
(Iclusig®) targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation
8-K
EX-99.1
INCY
Incyte Corp.
13 Feb 24
Provides 2024 Financial Guidance and Highlights R&D Priorities
7:03am
]. Wilmington, DE: Incyte; 2020.
About Iclusig® (ponatinib) tablets
Ponatinib (Iclusig®) targets not only native BCR-ABL but also its isoforms
8-K
EX-99.1
pmnc7 vvb
31 Oct 23
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates
7:05am
8-K
EX-99.1
8eozpg2vjkdwg5ra4z8
1 Aug 23
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates
7:05am
8-K
EX-99.1
375k8z4f3 lbi7q1
2 May 23
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
7:01am
8-K
EX-99.1
88zcmtq
1 Nov 22
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key
7:05am
8-K
EX-99.1
8ka0jrximgmoir1i
3 May 22
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key
7:16am